Last kr33.90 SEK
Change Today -0.30 / -0.88%
Volume 95.1K
ACTI On Other Exchanges
Symbol
Exchange
Stuttgart
Stockholm
OTC US
OTC US
As of 10:59 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

active biotech ab (ACTI) Snapshot

Open
kr34.50
Previous Close
kr34.20
Day High
kr34.50
Day Low
kr33.60
52 Week High
12/3/13 - kr81.50
52 Week Low
03/28/14 - kr27.50
Market Cap
2.5B
Average Volume 10 Days
150.4K
EPS TTM
kr-2.28
Shares Outstanding
74.9M
EX-Date
02/15/01
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTIVE BIOTECH AB (ACTI)

Related News

No related news articles were found.

active biotech ab (ACTI) Related Businessweek News

No Related Businessweek News Found

active biotech ab (ACTI) Details

Active Biotech AB (publ), a biotechnology company, focuses on developing pharmaceuticals for the treatment of autoimmune/inflammatory diseases and cancer in Sweden. Its projects include Laquinimod, an orally administered compound in Phase III clinical trial development for the treatment of autoimmune diseases, primarily multiple sclerosis; Tasquinimod, which is in Phase III clinical trial for the treatment of prostate cancer; and ANYARA, a protein drug in Phase II/III study for the treatment of renal cell cancer. The company is also developing Paquinimod (57-57), a compound primarily for the treatment of systemic sclerosis; and RhuDex, a compound that is primarily intended to be used as a drug for the treatment of rheumatoid arthritis. Its preclinical project product is ISI (inhibition of S100 interactions) for producing patentable chemical compounds that interact with S100A9, a target molecule for the quinoline compounds. Active Biotech AB (publ) is headquartered in Lund, Sweden.

58 Employees
Last Reported Date: 08/7/14

active biotech ab (ACTI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.0M
Compensation as of Fiscal Year 2013.

active biotech ab (ACTI) Key Developments

Active Biotech AB Reports Unaudited Consolidated and Company Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Active Biotech AB reported unaudited consolidated and company earnings results for second quarter and six months ended June 30, 2014. For the quarter, on consolidated basis, the company’s net sales were SEK 2.7 million against SEK 2.5 million a year ago. Operating loss was SEK 57.9 million against SEK 79.5 million a year ago. Loss before tax was SEK 58.2 million against SEK 81.7 million a year ago. Net loss for the period was SEK 57.7 million against SEK 81.2 million a year ago. Comprehensive loss per share before and after dilution was SEK 0.77 against SEK 1.08 a year ago. For the six months, on consolidated basis, the company’s net sales were SEK 4.9 million against SEK 5.0 million a year ago. Operating loss was SEK 117.2 million against SEK 156.5 million a year ago. Loss before tax was SEK 119.0 million against SEK 160.3 million a year ago. Net loss for the period was SEK 117.9 million against SEK 159.2 million a year ago. Comprehensive loss per share before and after dilution was SEK 1.57 against SEK 2.18 a year ago. Cash used in operating activities was SEK 149.7 million against SEK 93.1 million a year ago. Investments in tangible fixed assets was SEK 0.1 million against SEK 0.1 million a year ago. For the quarter, the company’s net sales were SEK 4.6 million against SEK 4.5 million a year ago. Operating loss was SEK 63.8 million against SEK 85.5 million a year ago. Net loss for the period was SEK 62.4 million against SEK 83.9 million a year ago. For the six months, the company’s net sales were SEK 9.6 million against SEK 9.9 million a year ago. Operating loss was SEK 128.3 million against SEK 167.5 million a year ago. Net loss for the period was SEK 126.3 million against SEK 165.9 million a year ago.

Active Biotech AB Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 04:30 PM

Active Biotech AB Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 04:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Tomas Leanderson, Chief Executive Officer and President.

Active Biotech AB (publ) Reports Consolidated and Parent Earnings Results for First Quarter Ended March 31, 2014

Active Biotech AB (publ) reported consolidated and parent earnings results for first quarter ended March 31, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 2.1 million compared to net sales of SEK 2.4 million for the same period a year ago. Operating loss was SEK 59.2 million compared to SEK 77.0 million last year. Loss attributable to parent company shareholders was SEK 60.2 million or SEK 0.80 per share before dilution and after dilution compared to SEK 78.0 million or SEK 1.10 per share before dilution and after dilution last year. Loss before tax was SEK 60.8 million compared to SEK 78.6 million last year. Cash used in operating activities was SEK 80.5 million compared to SEK 13.1 million last year. Investments in tangible fixed assets were s SEK 0.1 million last year. The change in earnings compared with the year-earlier period was attributable to lower research costs due to the ongoing Phase III tasquinimod trial being fully enrolled since December 2012 and the fact that the patients are now in the treatment phase. For the quarter, on parent basis, the company reported net sales of SEK 5.0 million compared to net sales of SEK 5.3 million for the same period a year ago. Operating loss was SEK 64.5 million compared to SEK 82.0 million last year. Loss was SEK 63.9 million compared to SEK 81.9 million last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACTI:SS kr33.90 SEK -0.30

ACTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACTI.
View Industry Companies
 

Industry Analysis

ACTI

Industry Average

Valuation ACTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.4x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTIVE BIOTECH AB, please visit www.activebiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.